PTPRD and non-small cell lung carcinoma: A favorable ORR was observed in PTPRD mutation patients in both the NSCLC (67% vs 29%, p=0.011, Fig. 2h) and ns-NSCLC subgroups (69% vs 28%, p=0.013, Fig. 2i).